| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cocaine | 22 | 2020 | 958 | 2.370 |
Why?
|
| tat Gene Products, Human Immunodeficiency Virus | 5 | 2022 | 119 | 2.100 |
Why?
|
| Anabolic Agents | 5 | 2024 | 256 | 1.970 |
Why?
|
| Magnetic Resonance Spectroscopy | 16 | 2020 | 3769 | 1.690 |
Why?
|
| Brain | 44 | 2024 | 27100 | 1.340 |
Why?
|
| Testosterone Congeners | 3 | 2021 | 62 | 1.340 |
Why?
|
| Androgens | 6 | 2024 | 1285 | 1.320 |
Why?
|
| Cocaine-Related Disorders | 10 | 2019 | 461 | 1.020 |
Why?
|
| Tobacco Use Disorder | 5 | 2012 | 703 | 1.010 |
Why?
|
| Brain Chemistry | 7 | 2015 | 960 | 0.990 |
Why?
|
| Substance Withdrawal Syndrome | 4 | 2023 | 625 | 0.970 |
Why?
|
| Cues | 8 | 2024 | 875 | 0.920 |
Why?
|
| Morphine Dependence | 1 | 2023 | 27 | 0.890 |
Why?
|
| Saimiri | 9 | 2019 | 334 | 0.870 |
Why?
|
| Glutamic Acid | 5 | 2020 | 1175 | 0.800 |
Why?
|
| Putamen | 7 | 2011 | 292 | 0.680 |
Why?
|
| Smoking | 6 | 2012 | 9054 | 0.670 |
Why?
|
| Narcotics | 4 | 2023 | 335 | 0.660 |
Why?
|
| Drug-Seeking Behavior | 1 | 2019 | 46 | 0.640 |
Why?
|
| Gene Products, tat | 3 | 2015 | 111 | 0.630 |
Why?
|
| Glycine | 5 | 2019 | 661 | 0.630 |
Why?
|
| Substance-Related Disorders | 6 | 2024 | 4416 | 0.620 |
Why?
|
| Choline | 7 | 2020 | 515 | 0.600 |
Why?
|
| Acetylcysteine | 1 | 2019 | 260 | 0.580 |
Why?
|
| Gyrus Cinguli | 5 | 2020 | 1115 | 0.580 |
Why?
|
| Discrimination Learning | 1 | 2019 | 278 | 0.570 |
Why?
|
| Creatine | 5 | 2020 | 427 | 0.550 |
Why?
|
| Magnetic Resonance Imaging | 36 | 2024 | 36401 | 0.550 |
Why?
|
| Opioid-Related Disorders | 6 | 2023 | 2164 | 0.530 |
Why?
|
| Cognition | 6 | 2024 | 6988 | 0.530 |
Why?
|
| Caudate Nucleus | 7 | 2013 | 390 | 0.510 |
Why?
|
| Antimetabolites | 1 | 2016 | 129 | 0.510 |
Why?
|
| Smoking Cessation | 4 | 2011 | 2056 | 0.500 |
Why?
|
| Extinction, Psychological | 2 | 2019 | 371 | 0.500 |
Why?
|
| Deoxyglucose | 1 | 2016 | 333 | 0.500 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 1 | 2019 | 541 | 0.470 |
Why?
|
| Tranquilizing Agents | 1 | 2014 | 58 | 0.470 |
Why?
|
| Xenon | 1 | 2014 | 112 | 0.460 |
Why?
|
| Dog Diseases | 1 | 2013 | 141 | 0.400 |
Why?
|
| Methadone | 4 | 2006 | 321 | 0.400 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2017 | 739 | 0.380 |
Why?
|
| Macaca fascicularis | 1 | 2013 | 900 | 0.370 |
Why?
|
| Aspartic Acid | 5 | 2020 | 576 | 0.370 |
Why?
|
| Phosphorus | 2 | 2004 | 332 | 0.370 |
Why?
|
| Anesthetics, Inhalation | 1 | 2016 | 572 | 0.370 |
Why?
|
| Image Processing, Computer-Assisted | 9 | 2017 | 8998 | 0.360 |
Why?
|
| Nucleus Accumbens | 1 | 2013 | 366 | 0.360 |
Why?
|
| Limbic System | 2 | 2013 | 419 | 0.360 |
Why?
|
| Suicide | 1 | 2021 | 1601 | 0.340 |
Why?
|
| Prefrontal Cortex | 5 | 2021 | 2219 | 0.340 |
Why?
|
| Vasoconstriction | 3 | 2001 | 592 | 0.310 |
Why?
|
| tau Proteins | 1 | 2019 | 2093 | 0.300 |
Why?
|
| Energy Metabolism | 3 | 2017 | 2878 | 0.300 |
Why?
|
| Receptors, Nicotinic | 1 | 2011 | 495 | 0.300 |
Why?
|
| Animals | 36 | 2023 | 168202 | 0.300 |
Why?
|
| Dopamine Uptake Inhibitors | 3 | 2019 | 297 | 0.300 |
Why?
|
| Primates | 2 | 2020 | 521 | 0.280 |
Why?
|
| Anisotropy | 3 | 2016 | 1283 | 0.280 |
Why?
|
| Basal Ganglia | 4 | 2004 | 554 | 0.280 |
Why?
|
| Memory | 2 | 2014 | 2192 | 0.280 |
Why?
|
| Phosphocreatine | 3 | 2020 | 261 | 0.280 |
Why?
|
| Brain Mapping | 5 | 2020 | 6635 | 0.270 |
Why?
|
| Weight Lifting | 2 | 2024 | 130 | 0.270 |
Why?
|
| Inositol | 2 | 2019 | 215 | 0.260 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 3 | 2019 | 894 | 0.260 |
Why?
|
| Receptors, Serotonin | 3 | 1996 | 208 | 0.250 |
Why?
|
| Fear | 1 | 2014 | 1477 | 0.250 |
Why?
|
| Amyloid beta-Peptides | 1 | 2019 | 3839 | 0.250 |
Why?
|
| Blood Volume | 5 | 2004 | 547 | 0.240 |
Why?
|
| Cerebrovascular Circulation | 7 | 2004 | 2726 | 0.240 |
Why?
|
| Cerebellum | 3 | 2007 | 1501 | 0.240 |
Why?
|
| Cognition Disorders | 3 | 2015 | 3979 | 0.230 |
Why?
|
| Dementia | 1 | 2019 | 2686 | 0.230 |
Why?
|
| Heroin Dependence | 2 | 2004 | 172 | 0.230 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2013 | 1492 | 0.220 |
Why?
|
| Male | 61 | 2024 | 360402 | 0.220 |
Why?
|
| Doxycycline | 3 | 2015 | 344 | 0.210 |
Why?
|
| Nerve Tissue Proteins | 3 | 2013 | 4408 | 0.210 |
Why?
|
| Injections, Intravenous | 8 | 2013 | 1376 | 0.210 |
Why?
|
| Receptors, Drug | 3 | 1991 | 157 | 0.210 |
Why?
|
| Choroid Plexus | 3 | 1996 | 240 | 0.210 |
Why?
|
| Analgesics, Opioid | 2 | 2023 | 3805 | 0.210 |
Why?
|
| Adult | 47 | 2024 | 220995 | 0.200 |
Why?
|
| Hypertrophy | 2 | 2015 | 560 | 0.200 |
Why?
|
| Nitrogen | 1 | 2023 | 345 | 0.200 |
Why?
|
| Demyelinating Diseases | 1 | 2004 | 352 | 0.190 |
Why?
|
| Oxygen | 6 | 2023 | 4226 | 0.190 |
Why?
|
| HIV Infections | 3 | 2022 | 17342 | 0.190 |
Why?
|
| Wales | 1 | 2021 | 87 | 0.190 |
Why?
|
| Neuropsychological Tests | 4 | 2024 | 7050 | 0.190 |
Why?
|
| Self Administration | 2 | 2019 | 387 | 0.190 |
Why?
|
| Naltrexone | 1 | 2023 | 317 | 0.180 |
Why?
|
| Neural Pathways | 3 | 2020 | 3056 | 0.180 |
Why?
|
| Ethanol | 3 | 1998 | 1320 | 0.180 |
Why?
|
| Pyrrolidines | 2 | 2013 | 338 | 0.180 |
Why?
|
| Methylphenidate | 1 | 2004 | 488 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 7 | 2020 | 10754 | 0.170 |
Why?
|
| Autoradiography | 7 | 2006 | 728 | 0.170 |
Why?
|
| Dogs | 2 | 2017 | 3837 | 0.170 |
Why?
|
| Nerve Net | 1 | 2012 | 2290 | 0.170 |
Why?
|
| Attention | 1 | 2010 | 2396 | 0.170 |
Why?
|
| Crime | 1 | 2021 | 204 | 0.170 |
Why?
|
| England | 1 | 2021 | 526 | 0.170 |
Why?
|
| Glycine Dehydrogenase (Decarboxylating) | 1 | 2019 | 15 | 0.170 |
Why?
|
| Glycine Agents | 1 | 2019 | 16 | 0.170 |
Why?
|
| Humans | 62 | 2024 | 760740 | 0.160 |
Why?
|
| Morphine | 1 | 2023 | 655 | 0.160 |
Why?
|
| Republic of Korea | 1 | 2021 | 583 | 0.160 |
Why?
|
| Animals, Genetically Modified | 2 | 2015 | 1557 | 0.160 |
Why?
|
| Dopamine | 3 | 2019 | 1606 | 0.160 |
Why?
|
| Narcotic Antagonists | 1 | 2023 | 585 | 0.160 |
Why?
|
| Phosphatidylinositols | 3 | 1996 | 282 | 0.150 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2020 | 2400 | 0.150 |
Why?
|
| Free Radical Scavengers | 1 | 2019 | 211 | 0.150 |
Why?
|
| Affective Disorders, Psychotic | 1 | 2019 | 186 | 0.150 |
Why?
|
| Principal Component Analysis | 2 | 2012 | 943 | 0.150 |
Why?
|
| Menstrual Cycle | 1 | 2001 | 539 | 0.140 |
Why?
|
| Conditioning, Operant | 1 | 2019 | 309 | 0.140 |
Why?
|
| Paroxetine | 3 | 2003 | 182 | 0.140 |
Why?
|
| Disease Models, Animal | 8 | 2019 | 18220 | 0.140 |
Why?
|
| Australia | 1 | 2021 | 1249 | 0.140 |
Why?
|
| Neuroimmunomodulation | 1 | 2019 | 184 | 0.140 |
Why?
|
| Phosphorus Isotopes | 1 | 2017 | 124 | 0.140 |
Why?
|
| HIV-1 | 3 | 2022 | 6858 | 0.140 |
Why?
|
| Mice, Transgenic | 5 | 2022 | 9526 | 0.140 |
Why?
|
| Brazil | 1 | 2021 | 1229 | 0.140 |
Why?
|
| Amygdala | 2 | 2015 | 1353 | 0.140 |
Why?
|
| Blood Cells | 1 | 1998 | 305 | 0.140 |
Why?
|
| Dibutyryl Cyclic GMP | 1 | 1996 | 6 | 0.140 |
Why?
|
| Photic Stimulation | 3 | 2019 | 1987 | 0.130 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2014 | 4575 | 0.130 |
Why?
|
| Mice | 10 | 2023 | 81368 | 0.130 |
Why?
|
| AIDS Dementia Complex | 2 | 2012 | 153 | 0.130 |
Why?
|
| Random Allocation | 2 | 2019 | 2392 | 0.130 |
Why?
|
| Central Nervous System Stimulants | 1 | 2004 | 1177 | 0.130 |
Why?
|
| Second Messenger Systems | 2 | 1996 | 202 | 0.130 |
Why?
|
| Steroids | 1 | 2021 | 928 | 0.130 |
Why?
|
| Nitroprusside | 1 | 1996 | 272 | 0.130 |
Why?
|
| Hypogonadism | 2 | 2019 | 798 | 0.130 |
Why?
|
| Executive Function | 1 | 2024 | 1391 | 0.130 |
Why?
|
| Adrenocorticotropic Hormone | 2 | 2013 | 618 | 0.130 |
Why?
|
| Image Enhancement | 2 | 2004 | 2881 | 0.130 |
Why?
|
| Female | 41 | 2021 | 392203 | 0.130 |
Why?
|
| Tritium | 5 | 1994 | 706 | 0.130 |
Why?
|
| Emotions | 3 | 2014 | 2741 | 0.130 |
Why?
|
| Mazindol | 1 | 1994 | 13 | 0.120 |
Why?
|
| Cerebral Cortex | 3 | 2010 | 5776 | 0.120 |
Why?
|
| Seasons | 1 | 2021 | 1518 | 0.120 |
Why?
|
| Checklist | 1 | 2022 | 827 | 0.120 |
Why?
|
| Freezing Reaction, Cataleptic | 1 | 2014 | 41 | 0.120 |
Why?
|
| Violence | 1 | 2021 | 936 | 0.120 |
Why?
|
| Macaca mulatta | 2 | 2019 | 2328 | 0.120 |
Why?
|
| Tomography, Emission-Computed | 3 | 1998 | 1122 | 0.120 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2020 | 1140 | 0.120 |
Why?
|
| Fluoxetine | 3 | 2003 | 733 | 0.120 |
Why?
|
| Glial Fibrillary Acidic Protein | 2 | 2012 | 550 | 0.110 |
Why?
|
| Racemases and Epimerases | 1 | 2014 | 114 | 0.110 |
Why?
|
| Neurons | 1 | 2013 | 9436 | 0.110 |
Why?
|
| Septum Pellucidum | 1 | 2013 | 54 | 0.110 |
Why?
|
| Cyclic GMP | 1 | 1995 | 395 | 0.110 |
Why?
|
| Simian immunodeficiency virus | 1 | 2019 | 810 | 0.110 |
Why?
|
| Psychotropic Drugs | 1 | 2019 | 888 | 0.110 |
Why?
|
| Benzeneacetamides | 1 | 2013 | 36 | 0.110 |
Why?
|
| Analysis of Variance | 4 | 2011 | 6223 | 0.110 |
Why?
|
| Nerve Fibers, Unmyelinated | 1 | 2013 | 98 | 0.100 |
Why?
|
| Laboratory Animal Science | 1 | 2012 | 9 | 0.100 |
Why?
|
| Spleen | 1 | 1998 | 2286 | 0.100 |
Why?
|
| Reward | 1 | 2019 | 971 | 0.100 |
Why?
|
| Tetracycline | 1 | 2012 | 216 | 0.100 |
Why?
|
| Carrier Proteins | 4 | 1998 | 4937 | 0.100 |
Why?
|
| Regional Blood Flow | 3 | 2004 | 1496 | 0.100 |
Why?
|
| Receptors, Opioid, mu | 1 | 2013 | 167 | 0.100 |
Why?
|
| Receptors, Opioid, kappa | 1 | 2013 | 138 | 0.100 |
Why?
|
| Temperature | 1 | 2019 | 2224 | 0.100 |
Why?
|
| Glutamine | 1 | 2015 | 576 | 0.100 |
Why?
|
| Middle Aged | 16 | 2024 | 220603 | 0.100 |
Why?
|
| Conditioning, Classical | 1 | 2014 | 368 | 0.100 |
Why?
|
| Restraint, Physical | 1 | 2013 | 186 | 0.100 |
Why?
|
| Glomerular Filtration Rate | 1 | 2020 | 2174 | 0.100 |
Why?
|
| Temporal Lobe | 3 | 2010 | 1695 | 0.090 |
Why?
|
| Aging | 3 | 2022 | 8700 | 0.090 |
Why?
|
| Cerebrovascular Disorders | 1 | 1998 | 1474 | 0.090 |
Why?
|
| Case-Control Studies | 5 | 2017 | 22153 | 0.090 |
Why?
|
| Stroop Test | 1 | 2010 | 71 | 0.090 |
Why?
|
| Administration, Oral | 3 | 2009 | 4010 | 0.090 |
Why?
|
| Rats, Inbred WKY | 1 | 2010 | 150 | 0.090 |
Why?
|
| Hematocrit | 3 | 2001 | 623 | 0.090 |
Why?
|
| Rats, Inbred SHR | 1 | 2010 | 186 | 0.090 |
Why?
|
| Nanoparticles | 1 | 2022 | 1957 | 0.090 |
Why?
|
| Fentanyl | 1 | 2013 | 433 | 0.090 |
Why?
|
| Injections, Intramuscular | 1 | 2011 | 555 | 0.080 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2011 | 433 | 0.080 |
Why?
|
| Nicotinic Agonists | 1 | 2011 | 265 | 0.080 |
Why?
|
| Heterocyclic Compounds | 3 | 2001 | 245 | 0.080 |
Why?
|
| Tissue Distribution | 4 | 1994 | 2261 | 0.080 |
Why?
|
| Administration, Cutaneous | 1 | 2011 | 712 | 0.080 |
Why?
|
| Internal-External Control | 1 | 2010 | 358 | 0.080 |
Why?
|
| Depressive Disorder, Major | 2 | 2003 | 4764 | 0.080 |
Why?
|
| Corpus Striatum | 2 | 1993 | 1235 | 0.080 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2010 | 6016 | 0.080 |
Why?
|
| Models, Animal | 1 | 2015 | 2108 | 0.080 |
Why?
|
| Parietal Lobe | 2 | 2012 | 852 | 0.080 |
Why?
|
| Behavior, Animal | 2 | 2014 | 1872 | 0.070 |
Why?
|
| Phosphorylation | 1 | 2019 | 8311 | 0.070 |
Why?
|
| Oxidative Stress | 1 | 2019 | 3115 | 0.070 |
Why?
|
| Occipital Lobe | 1 | 2009 | 374 | 0.070 |
Why?
|
| Psychological Tests | 1 | 2009 | 639 | 0.070 |
Why?
|
| Schizophrenia | 2 | 2017 | 6929 | 0.070 |
Why?
|
| Rest | 1 | 2012 | 918 | 0.070 |
Why?
|
| Hippocampus | 2 | 2022 | 3762 | 0.070 |
Why?
|
| Organometallic Compounds | 3 | 2001 | 646 | 0.070 |
Why?
|
| Postmortem Changes | 1 | 2006 | 119 | 0.070 |
Why?
|
| Wakefulness | 1 | 2013 | 1264 | 0.070 |
Why?
|
| Nicotine | 1 | 2011 | 679 | 0.070 |
Why?
|
| Brain Damage, Chronic | 1 | 2007 | 266 | 0.070 |
Why?
|
| Quinolines | 1 | 2011 | 764 | 0.060 |
Why?
|
| Time Factors | 9 | 2011 | 39908 | 0.060 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2020 | 2252 | 0.060 |
Why?
|
| Stress, Physiological | 1 | 2013 | 1403 | 0.060 |
Why?
|
| Carbon Isotopes | 1 | 2006 | 458 | 0.060 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2012 | 1988 | 0.060 |
Why?
|
| Affect | 3 | 2004 | 1486 | 0.060 |
Why?
|
| Regression Analysis | 3 | 2012 | 6339 | 0.060 |
Why?
|
| Hydrocortisone | 1 | 2013 | 1819 | 0.060 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2016 | 2789 | 0.060 |
Why?
|
| Public Health | 1 | 2018 | 2671 | 0.060 |
Why?
|
| Astrocytes | 1 | 2012 | 1341 | 0.060 |
Why?
|
| Memory Disorders | 1 | 2011 | 1197 | 0.060 |
Why?
|
| Double-Blind Method | 8 | 2019 | 12333 | 0.060 |
Why?
|
| Psychotic Disorders | 1 | 2019 | 3220 | 0.060 |
Why?
|
| Protons | 1 | 2009 | 1112 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2016 | 8619 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2014 | 8165 | 0.050 |
Why?
|
| Dominance, Cerebral | 1 | 2004 | 623 | 0.050 |
Why?
|
| Image Interpretation, Computer-Assisted | 3 | 2005 | 3356 | 0.050 |
Why?
|
| Heart Rate | 4 | 2004 | 4181 | 0.050 |
Why?
|
| Echo-Planar Imaging | 2 | 1998 | 663 | 0.050 |
Why?
|
| Phospholipids | 2 | 2004 | 787 | 0.050 |
Why?
|
| Substance Abuse Detection | 1 | 2004 | 301 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 14649 | 0.050 |
Why?
|
| Hemodilution | 1 | 2001 | 120 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2012 | 5780 | 0.050 |
Why?
|
| Mice, Inbred C57BL | 3 | 2019 | 22117 | 0.050 |
Why?
|
| Rats | 3 | 2014 | 23716 | 0.050 |
Why?
|
| Alcoholism | 2 | 2004 | 1972 | 0.050 |
Why?
|
| Clathrin | 1 | 2022 | 257 | 0.050 |
Why?
|
| Progesterone | 2 | 2022 | 742 | 0.040 |
Why?
|
| Contrast Media | 5 | 2004 | 5305 | 0.040 |
Why?
|
| Gadolinium | 3 | 2001 | 959 | 0.040 |
Why?
|
| Fluorine | 1 | 2000 | 83 | 0.040 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2022 | 144 | 0.040 |
Why?
|
| Marijuana Abuse | 1 | 2004 | 411 | 0.040 |
Why?
|
| Bipolar Disorder | 1 | 2017 | 5091 | 0.040 |
Why?
|
| Alleles | 1 | 2011 | 6861 | 0.040 |
Why?
|
| Water-Electrolyte Balance | 1 | 2000 | 325 | 0.040 |
Why?
|
| Inflammation | 1 | 2019 | 10759 | 0.040 |
Why?
|
| Follicular Phase | 1 | 1999 | 143 | 0.040 |
Why?
|
| Luteal Phase | 1 | 1999 | 138 | 0.040 |
Why?
|
| Sex Factors | 2 | 2004 | 10549 | 0.040 |
Why?
|
| Recurrence | 1 | 2011 | 8426 | 0.040 |
Why?
|
| Poisson Distribution | 1 | 2000 | 504 | 0.040 |
Why?
|
| Polycythemia | 1 | 1999 | 124 | 0.040 |
Why?
|
| Synaptic Transmission | 1 | 2004 | 1169 | 0.040 |
Why?
|
| Alprazolam | 1 | 1998 | 103 | 0.040 |
Why?
|
| Thalamus | 1 | 2004 | 1047 | 0.040 |
Why?
|
| Adenosine Triphosphate | 1 | 2004 | 1988 | 0.040 |
Why?
|
| Crack Cocaine | 1 | 1998 | 32 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2022 | 846 | 0.040 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2022 | 602 | 0.040 |
Why?
|
| Estradiol | 2 | 2022 | 1937 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2013 | 4488 | 0.040 |
Why?
|
| Blood Pressure | 3 | 2004 | 8473 | 0.040 |
Why?
|
| Alzheimer Disease | 1 | 2019 | 8603 | 0.040 |
Why?
|
| Parkinson Disease | 1 | 1991 | 2878 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2001 | 1575 | 0.040 |
Why?
|
| Syndrome | 1 | 2003 | 3268 | 0.030 |
Why?
|
| Morbidity | 1 | 2022 | 1750 | 0.030 |
Why?
|
| Neurosecretory Systems | 1 | 2018 | 223 | 0.030 |
Why?
|
| Receptors, Dopamine D1 | 1 | 1998 | 292 | 0.030 |
Why?
|
| Risk Factors | 2 | 2019 | 74128 | 0.030 |
Why?
|
| Neuropsychology | 1 | 1997 | 107 | 0.030 |
Why?
|
| Hemoglobins | 2 | 1999 | 1524 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2004 | 1431 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2011 | 64572 | 0.030 |
Why?
|
| von Willebrand Factor | 1 | 1999 | 676 | 0.030 |
Why?
|
| Anti-Anxiety Agents | 1 | 1998 | 397 | 0.030 |
Why?
|
| Neurogenesis | 1 | 2022 | 862 | 0.030 |
Why?
|
| Spiperone | 1 | 1995 | 31 | 0.030 |
Why?
|
| Ketanserin | 1 | 1995 | 24 | 0.030 |
Why?
|
| Swine | 2 | 1996 | 5908 | 0.030 |
Why?
|
| Mianserin | 1 | 1995 | 51 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2019 | 1756 | 0.030 |
Why?
|
| Drug Tolerance | 1 | 1996 | 367 | 0.030 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 2 | 1998 | 1068 | 0.030 |
Why?
|
| Reference Values | 3 | 2001 | 4919 | 0.030 |
Why?
|
| Analgesics | 1 | 2020 | 1067 | 0.030 |
Why?
|
| Papio | 1 | 1995 | 669 | 0.030 |
Why?
|
| Iodine Radioisotopes | 2 | 1998 | 1031 | 0.030 |
Why?
|
| Binding Sites | 2 | 1992 | 6051 | 0.030 |
Why?
|
| United States | 1 | 2021 | 72292 | 0.030 |
Why?
|
| Membrane Transport Proteins | 1 | 1998 | 1034 | 0.030 |
Why?
|
| Cerebral Angiography | 1 | 1998 | 1281 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 15908 | 0.020 |
Why?
|
| Testosterone | 1 | 2022 | 2472 | 0.020 |
Why?
|
| HIV Seropositivity | 1 | 1997 | 959 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 26065 | 0.020 |
Why?
|
| Hemodynamics | 2 | 1998 | 4160 | 0.020 |
Why?
|
| Exploratory Behavior | 1 | 2011 | 276 | 0.020 |
Why?
|
| Frontal Lobe | 1 | 1997 | 1418 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2019 | 2020 | 0.020 |
Why?
|
| Hypertension | 1 | 2010 | 8532 | 0.020 |
Why?
|
| Maze Learning | 1 | 2011 | 482 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2006 | 6483 | 0.020 |
Why?
|
| Comorbidity | 1 | 2004 | 10507 | 0.020 |
Why?
|
| Cattle | 1 | 1995 | 3841 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 6305 | 0.020 |
Why?
|
| Reproducibility of Results | 3 | 2022 | 20077 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2001 | 6346 | 0.020 |
Why?
|
| Depressive Disorder | 1 | 2000 | 3735 | 0.020 |
Why?
|
| Membrane Glycoproteins | 1 | 1998 | 3688 | 0.020 |
Why?
|
| Age of Onset | 1 | 2013 | 3303 | 0.020 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 2007 | 165 | 0.020 |
Why?
|
| Serotonin | 1 | 1990 | 1041 | 0.020 |
Why?
|
| Muscle Contraction | 1 | 1990 | 1200 | 0.020 |
Why?
|
| Anxiety | 1 | 2020 | 4573 | 0.020 |
Why?
|
| Thrombosis | 1 | 1999 | 2942 | 0.020 |
Why?
|
| Auditory Threshold | 1 | 1987 | 369 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2011 | 1470 | 0.020 |
Why?
|
| Noise | 1 | 1987 | 290 | 0.010 |
Why?
|
| Trachea | 1 | 1990 | 1089 | 0.010 |
Why?
|
| Research Design | 1 | 2000 | 6174 | 0.010 |
Why?
|
| Carbon Monoxide | 1 | 1987 | 547 | 0.010 |
Why?
|
| Calcium | 1 | 1996 | 5717 | 0.010 |
Why?
|
| Age Factors | 1 | 2019 | 18381 | 0.010 |
Why?
|
| Atrophy | 1 | 2007 | 1632 | 0.010 |
Why?
|
| Functional Laterality | 2 | 1998 | 2256 | 0.010 |
Why?
|
| Risk | 1 | 2013 | 9603 | 0.010 |
Why?
|
| Learning | 1 | 2010 | 1740 | 0.010 |
Why?
|
| Erythrocyte Count | 1 | 1999 | 157 | 0.010 |
Why?
|
| Blood Viscosity | 1 | 1999 | 124 | 0.010 |
Why?
|
| Aged | 3 | 2006 | 169092 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2007 | 4845 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 2007 | 1882 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2000 | 39062 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2004 | 2358 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2018 | 6826 | 0.010 |
Why?
|
| Axons | 1 | 2005 | 1671 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2020 | 41464 | 0.010 |
Why?
|
| Adolescent | 3 | 2013 | 88247 | 0.010 |
Why?
|
| Placebos | 1 | 2000 | 1667 | 0.010 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 1998 | 415 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2000 | 2214 | 0.010 |
Why?
|
| Acetazolamide | 1 | 1995 | 96 | 0.010 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2010 | 3708 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 1998 | 1369 | 0.010 |
Why?
|
| Phosphates | 1 | 1996 | 769 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2018 | 15498 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 1998 | 2079 | 0.010 |
Why?
|
| Vasodilator Agents | 1 | 1995 | 973 | 0.010 |
Why?
|
| Ligands | 1 | 1998 | 3268 | 0.010 |
Why?
|
| Hexamethonium Compounds | 1 | 1990 | 23 | 0.010 |
Why?
|
| Hexamethonium | 1 | 1990 | 17 | 0.010 |
Why?
|
| Young Adult | 1 | 2017 | 59191 | 0.010 |
Why?
|
| Atropine | 1 | 1990 | 244 | 0.010 |
Why?
|
| Serotonin Antagonists | 1 | 1990 | 144 | 0.010 |
Why?
|
| Phosphatidylinositol Phosphates | 1 | 1990 | 201 | 0.010 |
Why?
|
| Capsaicin | 1 | 1990 | 232 | 0.010 |
Why?
|
| Guinea Pigs | 1 | 1990 | 1310 | 0.000 |
Why?
|
| Sex Characteristics | 1 | 1999 | 2637 | 0.000 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1990 | 1058 | 0.000 |
Why?
|
| Binding, Competitive | 1 | 1990 | 1141 | 0.000 |
Why?
|
| Acetylcholine | 1 | 1990 | 629 | 0.000 |
Why?
|
| Brain Diseases | 1 | 1997 | 1546 | 0.000 |
Why?
|
| Audiometry, Pure-Tone | 1 | 1987 | 210 | 0.000 |
Why?
|
| Protein Kinase C | 1 | 1990 | 1202 | 0.000 |
Why?
|
| Epithelium | 1 | 1990 | 1603 | 0.000 |
Why?
|
| Rats, Inbred Strains | 1 | 1987 | 2088 | 0.000 |
Why?
|
| Models, Biological | 1 | 2001 | 9461 | 0.000 |
Why?
|
| Hearing Loss, Noise-Induced | 1 | 1987 | 144 | 0.000 |
Why?
|
| Protein Conformation | 1 | 1990 | 3965 | 0.000 |
Why?
|
| Body Mass Index | 1 | 1999 | 12942 | 0.000 |
Why?
|
| Amino Acid Sequence | 1 | 1990 | 13442 | 0.000 |
Why?
|
| Molecular Sequence Data | 1 | 1990 | 17630 | 0.000 |
Why?
|
| Aged, 80 and over | 1 | 1995 | 58919 | 0.000 |
Why?
|